CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer

CRISPR Therapeutics AG (NASDAQ:CRSP) on Monday provided updates on zugocaptagene geleucel (zugo-cel, formerly CTX112), its investigational allogeneic CAR T targeting CD19, in development for autoimmune disease and hematologic malignancies.Autoimmune DiseaseZugo-cel, targeting CD19, is in an ongoing Phase 1 basket trial in autoimmune rheumatologic diseases.Preliminary clinical data from the Phase 1 study have been encouraging, and zugo-cel has been well-tolerated to date.Also Read: CRISPR Therapeutics’ Inves ...